Elevation Oncology, Inc. (ELEV) News
Filter ELEV News Items
ELEV News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
ELEV News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ELEV News From Around the Web
Below are the latest news stories about ELEVATION ONCOLOGY INC that investors may wish to consider to help them evaluate ELEV as an investment opportunity.
Why Elevation Oncology (ELEV) Is Among the Best Penny Stocks to Invest In According to Media?We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to take a look at where Elevation Oncology, Inc. (NASDAQ:ELEV) stands against other best penny stocks to buy according to the media. Small-Cap Stocks Outlook for 2025 On December 24, Global […] |
Bipartisan lawmakers appear 'aligned' on PBM, insurance reformPresident-elect Donald Trump pledged earlier this week that he will "knock out the middlemen," in a jab against pharmacy benefit managers (PBMs). Major health insurers Cigna (CI), UnitedHealth Group (UNH), and CVS Health (CVS) saw their stock prices drop following this statement in Tuesday's session, but appear to be recovering in Wednesday trading. "They're helping patients kind of manage through the treatment paradigm with respect to which drugs to take, which formulary drugs are on, and kind of managing that whole process. So there is a benefit they are providing," Mizuho Healthcare Equity Strategist Jared Holz tells Madison Mills and Brad Smith on the Morning Brief. "Within the construct of the industry, there are so many players that are making tons of money in the middle here — w... |
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid TumorsElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the nomination of EO-1022 as its HER3 ADC development candidate. EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026. |
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating the combination potential of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC), with VEGFR2 or PD-1 inhibitors. The data will be presented in a poster session at the European Society for Medical Oncology Immuno-Onco |
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare ConferenceElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, President and Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. ET. |
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business AchievementsElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the third quarter ended September 30, 2024, and highlighted recent business achievements. |
What Makes Elevation Oncology (ELEV) a New Strong Buy StockElevation Oncology (ELEV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
Empery Asset Management's Strategic Acquisition in Elevation OncologyOn September 30, 2024, Empery Asset Management, LP (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 4,000,000 shares of Elevation Oncology Inc (NASDAQ:ELEV). This transaction, executed at a price of $0.5999 per share, represents a notable increase in the firm's stake in the biotechnology company. The trade has increased Empery Asset Managements total holdings in ELEV to a substantial 4.99% of the company, marking a strategic move within the healthcare sector. |
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to EO-3021, a differentiated antibody drug conjugate (ADC), for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) |
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 11:30 am ET. |